表紙
市場調查報告書

姿態性低血壓治療藥的全球市場:2019年∼2023年

Orthostatic Hypotension Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 906345
出版日期 內容資訊 英文 123 Pages
訂單完成後即時交付
價格
Back to Top
姿態性低血壓治療藥的全球市場:2019年∼2023年 Orthostatic Hypotension Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023
出版日期: 2019年08月08日內容資訊: 英文 123 Pages
簡介

全球姿態性低血壓(OH)治療藥市場上,老年人口中OH的盛行率的增加,OH的風險高的慢性疾病的盛行率增加,新興國家的OH治療藥的高市場成長機會等成為成長促進因素,在預測期間內預計將以約8%的年複合成長率擴大。但,低診斷率的不確定性,臨床證據的缺乏,OH治療藥不利的安全性,及第一選擇療法的非藥理學性治療選擇的採用等,可能妨礙在預測期間內姿態性低血壓治療藥市場成長。

本報告提供全球姿態性低血壓(OH)治療藥市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • Midodrine
  • Northera (droxidopa)
  • Fludrocortisone
  • 其他的治療藥物
  • 市場機會:各產品

第7章 客戶形勢

第8章 地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • OH治療藥的研究開發
  • OH治療的聯合治療的有效利用
  • 未認證的一次藥物療法的fludrocortisone的採用

第12章 業者情勢

  • 概要
  • 創造性破壞狀況

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Amneal Pharmaceuticals Inc.
  • H. Lundbeck AS
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31811

About this market

Orthostatic hypotension is the reduction in systolic blood pressure and can be divided into neurogenic and non-neurogenic forms. Technavio's orthostatic hypotension drugs market analysis considers sale from midodrine, northera (droxidopa), fludrocortisone, and other drugs. Our analysis also considers the orthostatic hypotension drugs market in Asia, Europe, North America, and ROW. In 2018, the midodrine segment had a significant share. However, the Northera (droxidopa) segment will grow faster and emerge as the market leader by the end of the forecast period. Northera can activate alpha 1 adrenergic receptors and have numerous physiological effects that may ameliorate the symptoms of nOH. This will contribute to the demand for Northera over the forecast period. Also, our global orthostatic hypotension drugs market report looks at factors such as increasing prevalence of OH in geriatric population, increasing prevalence of chronic diseases associated with high risk of OH, and high market growth opportunities for OH drugs in emerging countries. However, the uncertainties in low diagnosis rate, lack of clinical evidence and unfavorable safety profile of OH drugs, and adoption of non-pharmacological treatment options as first line therapy may hamper the growth of orthostatic hypotension drugs market over the forecast period.

Overview

Increasing prevalence of chronic diseases associated with high risk of OH

The prevalence of the neurodegenerative diseases, cardiovascular diseases and diabetes is significantly increasing worldwide, raising the risk of OH. It is associated with an underlying autonomic neurologic disorder. Dehydration is also a common condition in people which increases the risk of OH and causing damage to the nerves. This increase in prevalence of chronic diseases associated with high risk of OH will lead to the expansion of the global orthostatic hypotension drugs market at a CAGR of almost 8% during the forecast period.

Rise in the use of combination therapy in OH treatment

OH, is a chronic debilitating illness that is difficult to treat in several patients. Single drug therapy might not be adequate in treating OH patients as orthostatic stress varies with circumstances during the day. This has led to the increasing focus on the use of combination therapy in OH treatment. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global orthostatic hypotension drugs market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, global orthostatic hypotension drugs market is moderately fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several orthostatic hypotension drugs manufacturers, that include Amneal Pharmaceuticals Inc., H. Lundbeck AS, Mylan NV, Novartis AG, Pfizer Inc.

Also, orthostatic hypotension drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: Executive Summary

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Midodrine - Market size and forecast 2018-2023
  • Northera (droxidopa) - Market size and forecast 2018-2023
  • Fludrocortisone - Market size and forecast 2018-2023
  • Other drugs - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • R&D of new drugs for OH treatment
  • Use of combination therapy in OH treatment
  • Adoption of fludrocortisone as off-label first-line pharmacotherapy

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amneal Pharmaceuticals Inc.
  • H. Lundbeck AS
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Midodrine - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Midodrine - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Northera (droxidopa) - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Northera (droxidopa) - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Fludrocortisone - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Fludrocortisone - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Other drugs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Other drugs - Year-over-year growth 2019-2023 (%)
  • Exhibit 28: Market opportunity by product
  • Exhibit 29: Customer landscape
  • Exhibit 30: Market share by geography 2018-2023 (%)
  • Exhibit 31: Geographic comparison
  • Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: Amneal Pharmaceuticals Inc. - Vendor overview
  • Exhibit 49: Amneal Pharmaceuticals Inc. - Business segments
  • Exhibit 50: Amneal Pharmaceuticals Inc. - Organizational developments
  • Exhibit 51: Amneal Pharmaceuticals Inc. - Segment focus
  • Exhibit 52: Amneal Pharmaceuticals Inc. - Key offerings
  • Exhibit 53: H. Lundbeck AS - Vendor overview
  • Exhibit 54: H. Lundbeck AS - Business segments
  • Exhibit 55: H. Lundbeck AS - Organizational developments
  • Exhibit 56: H. Lundbeck AS - Geographic focus
  • Exhibit 57: H. Lundbeck AS - Key offerings
  • Exhibit 58: Mylan NV - Vendor overview
  • Exhibit 59: Mylan NV - Product segments
  • Exhibit 60: Mylan NV - Organizational developments
  • Exhibit 61: Mylan NV - Geographic focus
  • Exhibit 62: Mylan NV - Segment focus
  • Exhibit 63: Mylan NV - Key offerings
  • Exhibit 64: Novartis AG - Vendor overview
  • Exhibit 65: Novartis AG - Business segments
  • Exhibit 66: Novartis AG - Organizational developments
  • Exhibit 67: Novartis AG - Geographic focus
  • Exhibit 68: Novartis AG - Segment focus
  • Exhibit 69: Novartis AG - Key offerings
  • Exhibit 70: Pfizer Inc. - Vendor overview
  • Exhibit 71: Pfizer Inc. - Business segments
  • Exhibit 72: Pfizer Inc. - Organizational developments
  • Exhibit 73: Pfizer Inc. - Geographic focus
  • Exhibit 74: Pfizer Inc. - Segment focus
  • Exhibit 75: Pfizer Inc. - Key offerings
  • Exhibit 76: Validation techniques employed for market sizing
  • Exhibit 77: Definition of market positioning of vendors
Back to Top